Pregled bibliografske jedinice broj: 170775
ASSESSMENTS OF EXPANDED DISABILITY STATUS SCORE DURING BETA-INTERFERON THERAPY
ASSESSMENTS OF EXPANDED DISABILITY STATUS SCORE DURING BETA-INTERFERON THERAPY // European Journal of Neurology, 11 (suppl 2) (2004) (podatak o recenziji nije dostupan, kongresno priopcenje, znanstveni)
CROSBI ID: 170775 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
ASSESSMENTS OF EXPANDED DISABILITY STATUS SCORE DURING BETA-INTERFERON THERAPY
Autori
Lisak, Marijana ; Bošnjak Pašić, Marija ; Trkanjec, Zlarko ; Demarin, Vida
Izvornik
European Journal of Neurology (1351-5101) 11 (suppl 2)
(2004);
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, kongresno priopcenje, znanstveni
Ključne riječi
multiple sclerosis; EDSS
Sažetak
INTRODUCTION: Beta-interferon treatment reduces number of relapses and probably slows down progression of remitting-relapsing multiple sclerosis (RRMS). The study objective was to compare functional status of RRMS patients on beta-interferon therapy. MATERIALS AND METHODS: Twenty patients (9 males and 11 females ; 35, 75+/-8, 25 years (mean+/-SD age) with RRMS were treated with beta-interferon at University Department of Neurology, Sestre milosrdnice University Hospital: 7 patients were treated with interferon beta 1b (9, 6 MIU every other day) and 13 patients were treated with interferon beta 1a (6 MIU 3 times weekly). Kurtzke's Expanded Disability Status Score (EDSS) was recorded at baseline and six months after initiation of beta-interferon therapy. RESULTS: In interferon beta 1a group average EDSS score before therapy was 3.00 and after six months of therapy it decreased to 2, 92. In interferon beta 1b group average EDSS was 3.07 before therapy and decreased to 3, 00 after six month of treatment The average EDSS score was slightly smaller after six months of beta-interferon treatment in both groups, but the difference did not reach statistical significance (p=0.17 in interferon beta 1a group ; p=0.36 in interferon beta 1b group). There was no statistically significant difference in EDSS score in all patients before and six months after interferon therapy (p=0.083). CONCLUSION: Results of this study, in small group of RRMS patients showed only slight benefit of beta-interferon therapy. However, further research involving larger number of patients is required to get additional information about functional status of multiple sclerosis patients treated with beta-interferon.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE